ABOUT ONCOLOGYSTAT
Our Editorial Board and Editorial Team
Press Releases and Press Coverage
OUR MISSION
OncologySTAT's mission is to promote state-of-the-art cancer care by providing oncology professionals with instant online access to the highest-quality news, expert opinion, and clinical information.
OUR CONTENT
OncologySTAT offers an unparalleled array of professional cancer research, information, and education resources in a single online destination, with a breadth and depth of content that is unrivaled.
All site content is organized by 29 cancer types, enabling oncologists to instantly and easily access the latest news, scientific updates, and expert opinion pertaining to their specialty.
You will find:
- Journal Articles: OncologySTAT identifies the latest and most important articles from the most respected sources in oncology
- Abstracts are available when the publisher grants permission
- Summaries are created when the publisher does not grant permission for the abstract
- And, in come cases, we are able to offer free access to full text
- Journal Scans: Our editors constantly scan the newest, most important journals, flagging the articles that are critical to oncologists. Those articles are highlighted on OncologySTAT.
- Expert Commentary: In addition, we provide commentary from key opinion leaders to put key articles in perspective
- Take-Home Message: A brief overview of research article findings
- CME programs
- News: Premier medical and pharmaceutical news provided by Elsevier Global Medical News and FDC Reports
- Viewpoints: Interviews and commentary with thought leaders on practice-changing clinical trials and controversial topics
- Conference Coverage: Coverage of the most important oncology meetings, including pre-meeting recommendations from experts, news coverage during the conference, and videos and expert analyses of studies relevant to your patients.
- Chemotherapy regimens
- Oncology drug information
- Key Point Summaries: from Abeloff's Clinical Oncology (4th edition)
Key features of the site include:
- Weekly Newsletters: InfoBLAST, News and Journal Scans bring you the latest in your cancer area of interest
- RSS Feeds: are available for News, Journal Scans and Commentary
- Integrated Medline search
OUR ADVISORY BOARD
OncologySTAT is guided by a world-renowned Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. The Advisory Board includes 2 past presidents of ASCO.
OUR EDITORIAL BOARD AND EDITORIAL TEAM
The OncologySTAT editorial team is led by an esteemed Editorial Board—Editor-in-Chief Lee S. Schwartzberg, MD, FACP, and Associate Editors, Isabel Cunningham, MD, and Axel Grothey, MD. These physician editors apply their diverse experiences in clinical oncology practice, academia, and research to ensure that all of OncologySTAT’s editorial content fulfills the site’s primary mission. They also contribute monthly commentary on newsworthy and often controversial issues relevant to oncology practice. The editorial team consists of physicians, oncology fellows, and experienced medical writers and editors.
Editor-in-Chief: Lee S. Schwartzberg, MD, FACP
Associate Editor: Isabel Cunningham, MD
Associate Editor: Axel Grothey, MD
Web Content Manager: Megan Doremus
Associate Online Publisher: Lauren Scott-Zoeller
Medical Editors: Jane Velker
Contributors: Patrick W. Cobb, MD, FACP,
Alissa Marr, MD, Alberto Mizrachi, MD, Patrick Morris, MD, Ted Okon, David Portnoy, MD, Ryan Ramaekers, MD, Joleen Hubbard, MD, Fahd Quddus, MD, Sonia Reichert, MD, Basem M. William, MD, MRCP(UK)
HOW WE GET PAID
OncologySTAT is commercially supported by online advertising, sponsorship, and educational grants. Individual access to OncologySTAT is free. Premium content is available to any user who registers with the site.
While OncologySTAT is a commercially-sponsored product, it maintains the highest level of academic rigor, objectivity, and fair balance associated with all Elsevier products. No editorial content on the site is influenced in any way by commercial sponsors or content contributors.
EDUCATIONAL PROGRAMS
OncologySTAT provides a targeted online delivery channel for accredited and nonaccredited eCME/CME programs to cancer care and research professionals around the world. OncologySTAT can facilitate the delivery of live interactive educational programs, as well as preexisting educational content that can be hosted and delivered on-demand for a specified time period. For more information regarding OncologySTAT professional programs, please contact Neethu Joseph at n.joseph@elsevier.com.
STRATEGIC ALLIANCES
OncologySTAT invites inclusion of high-quality basic, clinical, and translational research articles, news, conference coverage, original content, and educational programs from recognized publishers, societies, and research organizations. We also welcome reciprocal linking arrangements with reputable cancer information and research websites.
For more information regarding OncologySTAT content integration and partnership opportunities, please contact Mark Placito at m.placito@elsevier.com.
ABOUT ELSEVIER
Elsevier is a world-leading publisher of scientific, technical, and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7000 employees in over 70 offices worldwide publish more than 2000 journals and 1900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands, and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK, and ENL (New York Stock Exchange).
Last Revised: October 18, 2011
Sign up for our newsletters
Too busy to follow cancer's top stories? Sign-up for one or more of our leading newsletters -- delivered weekly to your inbox.
